Evidence map›Paper›PMID 24891325›Full record

ArticleThorax2014

Human mesenchymal stem cells reduce the severity of acute lung injury in a sheep model of bacterial pneumonia.

Sven Asmussen, Hiroshi Ito, Daniel L Traber, Jae W Lee, Robert A Cox, Hal K Hawkins, Daniel F McAuley, David H McKenna, Lillian D Traber, Hanjing Zhuo and 6 more

2 registry-linked trialsAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Thorax, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 86 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
86citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01775774 phase1completednot on this map

A Phase 1 Multi-center Clinical Trial of Allogeneic Bone Marrow-derived Human Mesenchymal Stem Cells for the Treatment of Acute Respiratory Distress Syndrome

TypeinterventionalSponsorMichael A. MatthayRan2013 to 2015Enrolled9ConditionsAcute Respiratory Distress SyndromeArmsAllogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells
NCT02097641 phase2completednot on this map

Prospective, Randomized, Multi-center Phase 2 Clinical Trial of Allogeneic Bone Marrow-derived Human Mesenchymal Stromal Cells (hMSCs) for the Treatment of Acute Respiratory Distress Syndrome (ARDS)

TypeinterventionalSponsorMichael A. MatthayRan2014 to 2018Enrolled60ConditionsRespiratory Distress Syndrome, AdultArmsAllogeneic Bone Marrow-Derived Human Mesenchymal Stromal Cells, Plasma-Lyte A
3 · Its place in the literature

Who cites it

86 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Review
  8. Review
  9. Mechanisms of impaired alveolar fluid clearance.Anatomical record (Hoboken, N.J. : 2007) · 2025
    Review
  10. Review
  11. Article
  12. Article
  13. Viral airway injury promotes cell engraftment in an in vitro model of cystic fibrosis cell therapy.American journal of physiology. Lung cellular and molecular physiology · 2024
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

26 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Sven AsmussenDepartment of Anesthesiology, The University of Texas Medical Branch, Galveston, Texas, USA.
Hiroshi ItoDepartment of Anesthesiology, The University of Texas Medical Branch, Galveston, Texas, USA.
Daniel L TraberDepartment of Anesthesiology, The University of Texas Medical Branch, Galveston, Texas, USA.
Jae W LeeDepartments of Medicine & Anesthesiology, Cardiovascular Research Institute, The University of California San Francisco, San Francisco, California, USA.
Robert A CoxDepartment of Anesthesiology, The University of Texas Medical Branch, Galveston, Texas, USA.
Hal K HawkinsDepartment of Anesthesiology, The University of Texas Medical Branch, Galveston, Texas, USA.
Daniel F McAuleyDepartments of Medicine & Anesthesiology, Cardiovascular Research Institute, The University of California San Francisco, San Francisco, California, USA Centre for Infection and Immunity, The Queen's University of Belfast, Belfast, Northern Ireland, UK.
David H McKennaProduction Assistance in Cellular Therapy, University of Minnesota, Saint Paul, Minnesota, USA.
Lillian D TraberDepartment of Anesthesiology, The University of Texas Medical Branch, Galveston, Texas, USA.
Hanjing ZhuoDepartments of Medicine & Anesthesiology, Cardiovascular Research Institute, The University of California San Francisco, San Francisco, California, USA.
Jennifer WilsonDepartments of Medicine & Anesthesiology, Cardiovascular Research Institute, The University of California San Francisco, San Francisco, California, USA.
David N HerndonShriners Hospital for Children, Galveston, Texas, USA.
Donald S ProughDepartment of Anesthesiology, The University of Texas Medical Branch, Galveston, Texas, USA.
Kathleen D LiuDepartments of Medicine & Anesthesiology, Cardiovascular Research Institute, The University of California San Francisco, San Francisco, California, USA.
Michael A MatthayDepartments of Medicine & Anesthesiology, Cardiovascular Research Institute, The University of California San Francisco, San Francisco, California, USA.
Perenlei EnkhbaatarDepartment of Anesthesiology, The University of Texas Medical Branch, Galveston, Texas, USA.

Funding

Allogeneic Human Mesenchymal Stem Cells for the Treatment of Acute Lung InjuryU01HL108713 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MATTHAY, MICHAEL A. · 2011 to 2015
$5.1M
Etiology of Microvascular Changes in Gram-positive Sepsis: Mechanisms and Therapeutic OptionsR01GM097480 · NIGMS · UNIVERSITY OF TEXAS MED BR GALVESTON · PI ENKHBAATAR, PERENLEI · 2012 to 2022
$2.7M
Medical Research Council G0701690NHLBI NIH HHS U01 HL108713NIGMS NIH HHS GM097480-01A1NIGMS NIH HHS R01 GM097480
6 · The paper itself

Abstract

backgroundHuman bone marrow-derived mesenchymal stem (stromal) cells (hMSCs) improve survival in mouse models of acute respiratory distress syndrome (ARDS) and reduce pulmonary oedema in a perfused human lung preparation injured with Escherichia coli bacteria. We hypothesised that clinical grade hMSCs would reduce the severity of acute lung injury (ALI) and would be safe in a sheep model of ARDS.

methodsAdult sheep (30-40 kg) were surgically prepared. After 5 days of recovery, ALI was induced with cotton smoke insufflation, followed by instillation of live Pseudomonas aeruginosa (2.5×10(11) CFU) into both lungs under isoflurane anaesthesia. Following the injury, sheep were ventilated, resuscitated with lactated Ringer's solution and studied for 24 h. The sheep were randomly allocated to receive one of the following treatments intravenously over 1 h in one of the following groups: (1) control, PlasmaLyte A, n=8; (2) lower dose hMSCs, 5×10(6) hMSCs/kg, n=7; and (3) higher-dose hMSCs, 10×10(6) hMSCs/kg, n=4.

resultsBy 24 h, the PaO2/FiO2 ratio was significantly improved in both hMSC treatment groups compared with the control group (control group: PaO2/FiO2 of 97±15 mm Hg; lower dose: 288±55 mm Hg (p=0.003); higher dose: 327±2 mm Hg (p=0.003)). The median lung water content was lower in the higher-dose hMSC-treated group compared with the control group (higher dose: 5.0 g wet/g dry [IQR 4.9-5.8] vs control: 6.7 g wet/g dry [IQR 6.4-7.5] (p=0.01)). The hMSCs had no adverse effects.

conclusionsHuman MSCs were well tolerated and improved oxygenation and decreased pulmonary oedema in a sheep model of severe ARDS. TRAIL REGISTRATION NUMBER: NCT01775774 for Phase 1. NCT02097641 for Phase 2.

Indexed as

Mesenchymal Stem Cell TransplantationPseudomonas aeruginosaAdministration, IntravenousAnimalsAspartate AminotransferasesBronchoalveolar Lavage FluidDisease Models, AnimalHemodynamicsHumansHypoxiaLeukocyte CountNeutrophilsPneumonia, BacterialPseudomonas InfectionsPulmonary EdemaRandom AllocationAspartate AminotransferasesARDS

Identifiers

PMID24891325
PMCPMC4284068

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.